Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.


A hormone, thought to be produced by the kidneys, that regulates erythropoiesis, at least in higher vertebrates.



a hormone that stimulates the formation of erythrocytes in bone marrow. Characterized as a glycoprotein, erythropoietin has a carbohydrate content of 35 percent. It has a molecular weight of 30,000–40,000 and possesses antigenic properties. Erythropoietin is inactivated by neuraminidase, trypsin, chymotrypsin, and papain.

Erythropoietin was discovered by the French researchers F. Corneau and C. de Flandre in 1906 in rabbit serum that they tested after drawing blood. The hormone is found in low concentrations under normal physiological conditions, but the levels increase when the subject is in a state of hypoxia as a result of the loss of blood, a decrease in the oxygen content of the air, or various forms of anemia. Most scientists believe that erythropoietin is formed in the kidneys. When the hormone acts on stem cells in bone marrow, it causes their differentiation into cells of the erythroid series.


Fedorov, N. A., and M. G. Kakhetelidze. Eritropoetin. Moscow, 1973.
Normal’noe krovetvorenie i ego reguliatsiia. Moscow, 1976.
Gordon, A. S. Regulation of Hematopoiesis, vol. 1. New York [1970].


References in periodicals archive ?
Technavio's research study segments the global erythropoietin drugs market into regions including EMEA, Americas, APAC and EMEA.
Factors such as chronic bleeding, malignancy and infection had increased their resistance to erythropoietin therapy, in accord with reports of inflammatory and nutritional markers being associated with refractory anaemia (Locatelli et al.
Hypoxia of the kidney prompts synthesis and release of erythropoietin which travels to the bone marrow via the blood circulation and activates new red blood production.
Erythropoietin Protects the Kidney against the Injury and Dysfunction Caused by IschemiaReperfusion.
Cats being treated with erythropoietin must be carefully monitored for a sudden drop in PCV, as this may indicate an antibody reaction has begun.
Post-receptor (intracellular) effects of erythropoietin
Goldwasser failed to patent erythropoietin, allowing Amgen to become the owner of this very valuable franchise.
The $10 billion-a-year, worldwide market for chronic anemia drugs is dominated by injectable forms of recombinant erythropoietin, Akebia said.

Full browser ?